Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Elezanumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RADIUS-R
- Sponsors AbbVie
- 28 Oct 2022 Results of pooled analysis from NCT03737851and NCT03737812, evaluating Baseline MRI characteristics of multiple sclerosis patients, presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 15 Oct 2021 Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 13 Sep 2021 Status changed from active, no longer recruiting to completed.